Updates | Pfizer

ASH 2023: Advancing Potential Breakthroughs for Patients with Hematologic Disorders

Read more about ASH 2023: Advancing Potential Breakthroughs for Patients with Hematologic Disorders

This weekend, Pfizer will be joining the hematology/oncology community at the 65th Annual Meeting of the American Society of Hematology (ASH), the premier professional society of clinicians and scientists dedicated to conquering blood diseases.

November Social Media Round-Up—Vaccine Anniversary, Transgender Awareness, and the Corporate Equality Index

Read more about November Social Media Round-Up—Vaccine Anniversary, Transgender Awareness, and the Corporate Equality Index

Thanksgiving may have kicked off the holiday season, but November was chock full of things to celebrate all month long, including Transgender Awareness Week and Veterans Day.

Pfizer’s 2-in 1 At-Home Test Enables Convenient Testing for both COVID-19 and the Flu

Read more about Pfizer’s 2-in 1 At-Home Test Enables Convenient Testing for both COVID-19 and the Flu

When we think of winter, hot chocolate, cozy fireplaces, and catching up with friends and family often come to mind. But 'tis also peak respiratory virus season, with viruses like the flu and COVID-19 making the rounds at holiday parties and gatherings everywhere.

Listen Now: Award-Winning ‘Science Will Win’ Podcast Explores Antimicrobial Resistance

Read more about Listen Now: Award-Winning ‘Science Will Win’ Podcast Explores Antimicrobial Resistance

This week, season three of Pfizer’s signature Science Will Win podcast—which debuted as one of the top 1% podcasts globally—returns with a look at antimicrobial resistance (AMR), one of healthcare’s greatest threats, and the innovative ways doctors and scientists are leveraging emerging technology to fight it.

Pfizer CEO Albert Bourla Discusses Curing the Epidemic of Exclusion at APEC CEO Summit

Read more about Pfizer CEO Albert Bourla Discusses Curing the Epidemic of Exclusion at APEC CEO Summit

This week, the annual APEC CEO Summit was held in San Francisco, California. On Thursday, Pfizer CEO Albert Bourla delivered one of the Summit CEO Spotlight speeches, with remarks focused on “Curing the Epidemic of Exclusion.”

Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

Read more about Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

Recommended indication is not specific to patient gene mutation status, including homologous recombination repair (HRR) gene mutations

October Social Media Round-Up—Israel-Hamas War, COVID-19 Treatment News, and Pfizer Makes Forbes List

Read more about October Social Media Round-Up—Israel-Hamas War, COVID-19 Treatment News, and Pfizer Makes Forbes List

October was an eventful month, both around the world and here at Pfizer. In this edition of the monthly social media round-up, our leadership weighs in on both.

Pfizer's COVID-19 Oral Antiviral Treatment Transitioning from Government Distribution

Read more about Pfizer's COVID-19 Oral Antiviral Treatment Transitioning from Government Distribution

As COVID-19 continues to impact our communities, and winter approaches—bringing with it increases in respiratory infections—it’s important to stay vigilant and up to date on vaccines and to understand how to access treatment when appropriate.

Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices

Read more about Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices

PENBRAYA recommended for adolescents and young adults to help protect against the five leading causes of meningococcal disease
PENBRAYA provides the broadest serogroup coverage (meningococcal group A, B, C, W, and Y) of any licensed meningococcal vaccine available in the U.S.

NEW YORK, October 25, 2023 — Pfizer Inc. (NYSE:PFE) announced today that the U.S.

Accelerating Equity Takes the Spotlight at Pfizer’s Global DEI Summit

Read more about Accelerating Equity Takes the Spotlight at Pfizer’s Global DEI Summit

On September 21, over 7,000 Pfizer colleagues and external DEI experts came together at Pfizer NYC headquarters and via webcast for the 2023 Pfizer Global DEI Summit.

Subscribe to Updates